Shuttle Pharmaceuticals Holdings Inc (SHPH)

$1.08 +0.03 (2.86%)
Market Cap 1.68M
Revenue (ttm) 0.00
Net Income (ttm) -9.14M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 41,900
Avg Vol 3,171,608
Day's Range N/A - N/A
Shares Out 1.60M
Stochastic %K 42%
Beta -1.02
Analysts Strong Buy
Price Target N/A

Company Profile

Shuttle Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops novel therapies to cure cancers. The company is developing Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas; and SP-2-225, a pre-clinical class IIb product candidate that effects on the regulation of the immune system. It is also developing SP-1-303, a pre-clinical selective Class I HDAC for use in the treatment of ER positive breast cancers; and SP-1-161, a HD...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 240 403 4212
Address:
401 Professional Drive, Suite 260, Gaithersburg, United States
vu_jade
vu_jade Feb. 25 at 7:54 PM
$SHPH when this YOLO’s hold onto your panties
1 · Reply
BillionerOfKing
BillionerOfKing Feb. 21 at 1:14 PM
$SHPH Current Stock Price: $1.05
0 · Reply
vu_jade
vu_jade Feb. 19 at 4:11 PM
$SHPH more days like this.. some así news .. and bam,
1 · Reply
Ernstinvest
Ernstinvest Feb. 19 at 4:11 PM
$SHPH Down 60% since post😉
0 · Reply
vu_jade
vu_jade Feb. 18 at 6:58 PM
$SHPH It’s always the darkest At The bottom … ☀️
0 · Reply
vu_jade
vu_jade Feb. 18 at 3:45 PM
$SHPH shell companies trade higher
0 · Reply
JavierLindemann471
JavierLindemann471 Feb. 18 at 2:09 PM
$SHPH Biotech microcap with limited visibility.
0 · Reply
vu_jade
vu_jade Feb. 18 at 12:59 PM
$SHPH few hundred shares dropped it 20c .. lol
1 · Reply
vu_jade
vu_jade Feb. 17 at 8:25 PM
$SHPH time To start the reversal Targets: 2.50 $4 $10 +
0 · Reply
Dellbell
Dellbell Feb. 17 at 2:01 PM
$SHPH PT $10
0 · Reply
Latest News on SHPH
Utah Approves AI Prescriptions Drugs. How AI Is Saving Time, Cutting Costs - and Why Molecule.ai's Drug Discovery Platform Matters More Than Ever

Jan 13, 2026, 4:00 PM EST - 6 weeks ago

Utah Approves AI Prescriptions Drugs. How AI Is Saving Time, Cutting Costs - and Why Molecule.ai's Drug Discovery Platform Matters More Than Ever

Shuttle Pharmaceuticals Acquires AI Health Platform

Nov 21, 2025, 9:30 AM EST - 3 months ago

Shuttle Pharmaceuticals Acquires AI Health Platform

Shuttle Pharmaceuticals Announces Above-the-Market $2.5 Million Private Placement at Effective Price per Share of $4.00

Nov 3, 2025, 7:00 AM EST - 4 months ago

Shuttle Pharmaceuticals Announces Above-the-Market $2.5 Million Private Placement at Effective Price per Share of $4.00

Shuttle Pharma and the Moment Science Learned to Think for Itself (NASDAQ:SHPH)

Oct 22, 2025, 10:00 AM EDT - 4 months ago

Shuttle Pharma and the Moment Science Learned to Think for Itself (NASDAQ:SHPH)

Shuttle Pharma Positions to Become the First Self-Learning Biotech After Definitive LOI to Acquire Molecule.AI (NASDAQ:SHPH)

Oct 22, 2025, 7:00 AM EDT - 4 months ago

Shuttle Pharma Positions to Become the First Self-Learning Biotech After Definitive LOI to Acquire Molecule.AI (NASDAQ:SHPH)

Shuttle Pharma Turns Radiation Into a Smart Weapon With Definitive LOI for Molecule.ai (NASDAQ:SHPH)

Oct 21, 2025, 5:55 PM EDT - 4 months ago

Shuttle Pharma Turns Radiation Into a Smart Weapon With Definitive LOI for Molecule.ai (NASDAQ:SHPH)

Shuttle Pharmaceuticals to Acquire AI Molecular Modeling and Predictive Analytics Platform

Oct 21, 2025, 4:05 PM EDT - 4 months ago

Shuttle Pharmaceuticals to Acquire AI Molecular Modeling and Predictive Analytics Platform

Shuttle Executes LOI with Molecule.ai

Oct 10, 2025, 10:20 AM EDT - 4 months ago

Shuttle Executes LOI with Molecule.ai

Shuttle to Enter $3.24 Billion AI Pharmaceutical Market

Oct 9, 2025, 4:15 PM EDT - 4 months ago

Shuttle to Enter $3.24 Billion AI Pharmaceutical Market

Shuttle Pharma Provides Second Quarter 2025 Corporate Update

Aug 14, 2025, 4:05 PM EDT - 6 months ago

Shuttle Pharma Provides Second Quarter 2025 Corporate Update

Shuttle Pharmaceuticals Announces Closing of $4.25 Million Private Placement Priced At-the-Market

Jun 24, 2025, 4:10 PM EDT - 8 months ago

Shuttle Pharmaceuticals Announces Closing of $4.25 Million Private Placement Priced At-the-Market

Shuttle Pharmaceuticals Announces Pricing of $4.25 Million Private Placement Priced At-the-Market

Jun 20, 2025, 3:55 PM EDT - 8 months ago

Shuttle Pharmaceuticals Announces Pricing of $4.25 Million Private Placement Priced At-the-Market

Shuttle Pharma Announces Reverse Stock Split will Become Effective on June 16, 2025, at 12:01 a.m., Eastern Time

Jun 12, 2025, 12:00 PM EDT - 9 months ago

Shuttle Pharma Announces Reverse Stock Split will Become Effective on June 16, 2025, at 12:01 a.m., Eastern Time

Shuttle Pharma Announces Proposed Reverse Stock Split as Part of Strategic Nasdaq Compliance Initiative

Jun 12, 2025, 8:30 AM EDT - 9 months ago

Shuttle Pharma Announces Proposed Reverse Stock Split as Part of Strategic Nasdaq Compliance Initiative

Shuttle Pharma Appoints George Scorsis Chairman of the Board of Directors

Jun 4, 2025, 4:01 PM EDT - 9 months ago

Shuttle Pharma Appoints George Scorsis Chairman of the Board of Directors

Shuttle Pharma Provides Corporate Update

May 15, 2025, 4:45 PM EDT - 10 months ago

Shuttle Pharma Provides Corporate Update

Shuttle Pharma FDA Orphan-Drug Nears Patient Enrollment Milestone for Phase 2 Clinical Trial

May 8, 2025, 4:01 PM EDT - 10 months ago

Shuttle Pharma FDA Orphan-Drug Nears Patient Enrollment Milestone for Phase 2 Clinical Trial

Shuttle Pharma to Present at the Planet MicroCap Showcase: VEGAS 2025 on April 23, 2025

Apr 21, 2025, 4:15 PM EDT - 11 months ago

Shuttle Pharma to Present at the Planet MicroCap Showcase: VEGAS 2025 on April 23, 2025

Shuttle Pharma Developing Pretreatment Diagnostic Blood Tests for Prostate Cancer, Files Provisional Patent for PSMA Ligand Conjugates to Treat Prostate Cancer

Apr 10, 2025, 4:01 PM EDT - 11 months ago

Shuttle Pharma Developing Pretreatment Diagnostic Blood Tests for Prostate Cancer, Files Provisional Patent for PSMA Ligand Conjugates to Treat Prostate Cancer

Shuttle Pharma Announces Closing of $5.75 Million Underwritten Offering

Mar 13, 2025, 4:10 PM EDT - 1 year ago

Shuttle Pharma Announces Closing of $5.75 Million Underwritten Offering

Shuttle Pharma Announces Pricing of $5.75 Million Underwritten Offering

Mar 12, 2025, 9:24 AM EDT - 1 year ago

Shuttle Pharma Announces Pricing of $5.75 Million Underwritten Offering

Shuttle Pharma Announces Appointment of Christopher Cooper as Interim Co-CEO to Enhance Business Activities

Mar 12, 2025, 6:20 AM EDT - 1 year ago

Shuttle Pharma Announces Appointment of Christopher Cooper as Interim Co-CEO to Enhance Business Activities

Shuttle Pharma Provides Corporate Update and Reports 2024 Results

Feb 26, 2025, 10:45 AM EST - 1 year ago

Shuttle Pharma Provides Corporate Update and Reports 2024 Results

Shuttle Pharma to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025

Jan 7, 2025, 9:00 AM EST - 1 year ago

Shuttle Pharma to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025

Shuttle Pharma Expands Patient Enrollment for Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma as UVA Cancer Center Doses Its First Patient

Nov 26, 2024, 9:00 AM EST - 1 year ago

Shuttle Pharma Expands Patient Enrollment for Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma as UVA Cancer Center Doses Its First Patient

Shuttle Pharma Provides Third Quarter 2024 Corporate Update

Nov 13, 2024, 5:00 PM EST - 1 year ago

Shuttle Pharma Provides Third Quarter 2024 Corporate Update

Shuttle Pharmaceuticals Holdings, Inc. Announces Pricing of $4.5 Million Public Offering Priced At-The-Market Under Nasdaq Rules

Oct 29, 2024, 9:05 PM EDT - 1 year ago

Shuttle Pharmaceuticals Holdings, Inc. Announces Pricing of $4.5 Million Public Offering Priced At-The-Market Under Nasdaq Rules

Shuttle Pharma Completes Clinical Trial Site Enrollment for Phase 2 of Ropidoxuridine for Treatment of Patients with Glioblastoma

Oct 28, 2024, 4:05 PM EDT - 1 year ago

Shuttle Pharma Completes Clinical Trial Site Enrollment for Phase 2 of Ropidoxuridine for Treatment of Patients with Glioblastoma

Shuttle Pharma Expands Clinical Trial Site Enrollment for Phase 2 of Ropidoxuridine for Treatment of Patients with Glioblastoma

Sep 16, 2024, 9:00 AM EDT - 1 year ago

Shuttle Pharma Expands Clinical Trial Site Enrollment for Phase 2 of Ropidoxuridine for Treatment of Patients with Glioblastoma

Shuttle Pharma Provides Second Quarter 2024 Corporate Update

Sep 4, 2024, 4:15 PM EDT - 1 year ago

Shuttle Pharma Provides Second Quarter 2024 Corporate Update

Shuttle Pharma Receives Notice of Nasdaq Non-Compliance with Listing Rule 5250(c)(1)

Aug 26, 2024, 4:10 PM EDT - 1 year ago

Shuttle Pharma Receives Notice of Nasdaq Non-Compliance with Listing Rule 5250(c)(1)

Shuttle Pharma Ready to Enroll Patients in Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma

Aug 14, 2024, 4:10 PM EDT - 1 year ago

Shuttle Pharma Ready to Enroll Patients in Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma

Shuttle Pharma's Selective HDAC Inhibitor Exhibits ATM Activation and Modulation of ER Expression Resulting in Substantial Growth Inhibition of Estrogen Receptor Positive Breast Cancer Cells, as Reported in PLOS ONE

Jul 19, 2024, 9:00 AM EDT - 1 year ago

Shuttle Pharma's Selective HDAC Inhibitor Exhibits ATM Activation and Modulation of ER Expression Resulting in Substantial Growth Inhibition of Estrogen Receptor Positive Breast Cancer Cells, as Reported in PLOS ONE

Shuttle Pharma Appoints Timothy Lorber as Chief Financial Officer

Jun 18, 2024, 9:00 AM EDT - 1 year ago

Shuttle Pharma Appoints Timothy Lorber as Chief Financial Officer

Shuttle Pharma to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024

May 22, 2024, 4:15 PM EDT - 1 year ago

Shuttle Pharma to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024

Shuttle Pharma Provides First Quarter 2024 Corporate Update

May 14, 2024, 9:00 AM EDT - 1 year ago

Shuttle Pharma Provides First Quarter 2024 Corporate Update

Shuttle Pharmaceuticals to Present at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1, 2024 & 1x1 Meetings on Thursday, May 2, 2024

Apr 23, 2024, 4:15 PM EDT - 2 years ago

Shuttle Pharmaceuticals to Present at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1, 2024 & 1x1 Meetings on Thursday, May 2, 2024

Shuttle Pharmaceuticals to Present at the Emerging Growth Conference on April 4, 2024

Apr 3, 2024, 9:00 AM EDT - 2 years ago

Shuttle Pharmaceuticals to Present at the Emerging Growth Conference on April 4, 2024

Shuttle Pharma Provides Fourth Quarter 2023 Corporate Update

Mar 22, 2024, 9:00 AM EDT - 2 years ago

Shuttle Pharma Provides Fourth Quarter 2023 Corporate Update

Shuttle Pharmaceuticals to Present at the Emerging Growth Conference on March 6, 2024

Mar 5, 2024, 9:00 AM EST - 2 years ago

Shuttle Pharmaceuticals to Present at the Emerging Growth Conference on March 6, 2024

Shuttle Pharma Announces Its Intent to Pursue a Rights Offering

Feb 13, 2024, 8:00 AM EST - 2 years ago

Shuttle Pharma Announces Its Intent to Pursue a Rights Offering

Shuttle Pharma to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024

Jan 23, 2024, 4:30 PM EST - 2 years ago

Shuttle Pharma to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024

Shuttle Pharmaceuticals Receives FDA Approval to Proceed with Phase II Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma

Jan 8, 2024, 9:00 AM EST - 2 years ago

Shuttle Pharmaceuticals Receives FDA Approval to Proceed with Phase II Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma

Shuttle Pharmaceuticals Submits IND Application to the U.S. FDA for Ropidoxuridine Phase II Clinical Trial for Patients with Glioblastoma

Dec 11, 2023, 9:00 AM EST - 2 years ago

Shuttle Pharmaceuticals Submits IND Application to the U.S. FDA for Ropidoxuridine Phase II Clinical Trial for Patients with Glioblastoma

Shuttle Pharmaceuticals to Present at the Emerging Growth Conference on December 7, 2023

Nov 30, 2023, 9:00 AM EST - 2 years ago

Shuttle Pharmaceuticals to Present at the Emerging Growth Conference on December 7, 2023

Shuttle Pharmaceuticals Provides Third Quarter 2023 Corporate Update

Nov 14, 2023, 9:00 AM EST - 2 years ago

Shuttle Pharmaceuticals Provides Third Quarter 2023 Corporate Update

Shuttle Pharma Advances Prostate Cancer Predictive Biomarker Program Through Exclusive License Agreement

Oct 31, 2023, 9:00 AM EDT - 2 years ago

Shuttle Pharma Advances Prostate Cancer Predictive Biomarker Program Through Exclusive License Agreement

Shuttle Pharma to Participate in the Lytham Partners Fall 2023 Investor Conference

Oct 10, 2023, 9:00 AM EDT - 2 years ago

Shuttle Pharma to Participate in the Lytham Partners Fall 2023 Investor Conference

Shuttle Pharma Announces Results of Pre-IND Meeting with FDA for Ropidoxuridine Phase II Clinical Trial for Patients with Glioblastoma

Sep 25, 2023, 9:00 AM EDT - 2 years ago

Shuttle Pharma Announces Results of Pre-IND Meeting with FDA for Ropidoxuridine Phase II Clinical Trial for Patients with Glioblastoma

Shuttle Pharma Participates in Hampton University Proton Therapy Institute Prostate Cancer & Men's Health Fair

Sep 13, 2023, 9:00 AM EDT - 2 years ago

Shuttle Pharma Participates in Hampton University Proton Therapy Institute Prostate Cancer & Men's Health Fair

vu_jade
vu_jade Feb. 25 at 7:54 PM
$SHPH when this YOLO’s hold onto your panties
1 · Reply
BillionerOfKing
BillionerOfKing Feb. 21 at 1:14 PM
$SHPH Current Stock Price: $1.05
0 · Reply
vu_jade
vu_jade Feb. 19 at 4:11 PM
$SHPH more days like this.. some así news .. and bam,
1 · Reply
Ernstinvest
Ernstinvest Feb. 19 at 4:11 PM
$SHPH Down 60% since post😉
0 · Reply
vu_jade
vu_jade Feb. 18 at 6:58 PM
$SHPH It’s always the darkest At The bottom … ☀️
0 · Reply
vu_jade
vu_jade Feb. 18 at 3:45 PM
$SHPH shell companies trade higher
0 · Reply
JavierLindemann471
JavierLindemann471 Feb. 18 at 2:09 PM
$SHPH Biotech microcap with limited visibility.
0 · Reply
vu_jade
vu_jade Feb. 18 at 12:59 PM
$SHPH few hundred shares dropped it 20c .. lol
1 · Reply
vu_jade
vu_jade Feb. 17 at 8:25 PM
$SHPH time To start the reversal Targets: 2.50 $4 $10 +
0 · Reply
Dellbell
Dellbell Feb. 17 at 2:01 PM
$SHPH PT $10
0 · Reply
UgoGreg
UgoGreg Feb. 15 at 5:04 PM
$SHPH https://youtu.be/nCPt9XhiRxk
0 · Reply
vu_jade
vu_jade Feb. 13 at 8:54 PM
$SHPH just a shell company looking for a hermit crab
0 · Reply
vu_jade
vu_jade Feb. 13 at 8:47 PM
$SHPH brought my average down .. in 31 days I’ll sell the highest prints .. Good luck
0 · Reply
vu_jade
vu_jade Feb. 13 at 5:24 PM
$SHPH only place to go is up .. And if not it’s on $1 and a micro cap
0 · Reply
Kokoblack
Kokoblack Feb. 13 at 4:09 PM
$SHPH lets gamble its Friday fill my 10k shares beach
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 12 at 9:39 PM
$SHPH RSI: 13.43, MACD: -0.1619 Vol: 0.40, MA20: 1.82, MA50: 1.77 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
realditzy
realditzy Feb. 12 at 7:49 PM
$SHPH I don’t know what’s going on, but I’m loading up
0 · Reply
Marko1984
Marko1984 Feb. 12 at 7:27 PM
$SHPH WTF is going on with this POS
0 · Reply
Simo11
Simo11 Feb. 12 at 5:39 PM
$SHPH close green today
0 · Reply
vu_jade
vu_jade Feb. 12 at 3:04 AM
$SHPH today was the leg sweep day … Time to,start rallying …
0 · Reply
kasrde
kasrde Feb. 11 at 10:42 PM
$SHPH Started a small position.
0 · Reply
Simo11
Simo11 Feb. 11 at 6:14 PM
$SHPH $WLDS
0 · Reply